All Growth Hormone Peptides Ranked by Potency & Safety

<div class="answer-summary"> <p><strong>Quick answer:</strong> No single growth hormone peptide is best for everyone. Ipamorelin combined with CJC-1295 is the most widely used stack for balanced growth hormone release with few side effects. Tesamorelin has the strongest clinical evidence and is FDA-approved for HIV-associated lipodystrophy. Sermorelin is the gentlest and longest-studied. GHRP-6 drives strong release but causes intense hunger, and GHRP-2 is potent but can raise cortisol and prolactin. Note the shifting regulatory status: the FDA placed ipamorelin and CJC-1295 into a restricted compounding category in September 2023, then removed them from it in September 2024 and moved them into an ongoing advisory-committee review, so access depends on where that review lands.</p> </div>

What is the best growth hormone peptide?

There is no universal best. The right peptide depends on your goal, your tolerance for side effects, your budget, and what you can legally obtain. For most people seeking balanced release with minimal side effects, ipamorelin paired with CJC-1295 is the most popular choice. For evidence behind fat loss, tesamorelin leads. For a gentle, well-studied entry point, sermorelin stands out. The ranking below balances effectiveness, safety, evidence, and tolerability.

The quick ranking

1. Ipamorelin + CJC-1295: best overall for balanced, sustained release with minimal side effects.
2. Tesamorelin: best clinical evidence; FDA-approved for HIV lipodystrophy; strong for visceral fat.
3. Sermorelin: gentlest, longest track record, good entry point.
4. CJC-1295 (alone): long-acting GHRH analog for steady elevation.
5. Ipamorelin (alone): selective release with minimal side effects.
6. GHRP-2: potent release but raises cortisol and prolactin.
7. GHRP-6: strong release but intense hunger.
8. Hexarelin: most potent GHRP but desensitizes quickly.

How we ranked them

Each peptide was assessed on five factors: release potency, side-effect profile, clinical evidence, ease of use, and cost. Peptides that paired strong results with good safety and solid evidence ranked highest. Those with heavy side effects or rapid desensitization ranked lower despite high potency. Most of these compounds are investigational and not FDA-approved for anti-aging or performance, so the ranking reflects available evidence and reported use, not regulatory endorsement.

GHRH analogs

GHRH (growth hormone-releasing hormone) analogs prompt the pituitary to release growth hormone on its natural rhythm:

• Sermorelin: the original GHRH analog. Short half-life, gentle action, well studied. Good for beginners.
• CJC-1295: a modified GHRH analog with a longer half-life; the version with DAC lasts longer still, giving steadier elevation.
• Tesamorelin: the best-evidenced GHRH analog, FDA-approved as Egrifta for HIV-associated lipodystrophy, with strong data for visceral fat reduction.

GHRP and ghrelin mimetics

GHRPs (growth hormone-releasing peptides) and ghrelin mimetics act through a different receptor:

• Ipamorelin: the most selective GHRP. Stimulates release with little effect on cortisol, prolactin, or hunger. Very well tolerated.
• GHRP-2: potent release but can raise cortisol and prolactin and increase appetite.
• GHRP-6: strong release with intense hunger as a signature side effect.
• Hexarelin: the most potent GHRP, but the body desensitizes to it quickly, limiting long-term use.

GHRP-6 vs sermorelin, and ipamorelin vs GHRP-2

Two of the most common comparisons:

• GHRP-6 vs sermorelin: GHRP-6 is a ghrelin mimetic that drives strong release and intense hunger; sermorelin is a GHRH analog that is gentler with fewer side effects. They act through different receptors and are sometimes combined.
• Ipamorelin vs GHRP-2: ipamorelin is cleaner with fewer side effects; GHRP-2 produces stronger release but raises cortisol and prolactin. Most people prefer ipamorelin for long-term use because of its tolerability.

The best stacks

Combining a GHRH analog with a GHRP produces more release than either alone:

• Ipamorelin + CJC-1295: the standard combination. Balanced, sustained, minimal side effects.
• Sermorelin + GHRP-2: stronger release, but more side effects from the GHRP-2.
• Tesamorelin + ipamorelin: aimed at fat loss, pairing the best-evidenced GHRH with a clean GHRP.

Side effect comparison

Common effects include water retention, numbness or tingling, a brief head rush, and injection-site reactions. By peptide: ipamorelin is minimal; CJC-1295 brings mild water retention; sermorelin is mild, mostly injection-site; tesamorelin can cause joint discomfort; GHRP-2 raises cortisol and prolactin and appetite; GHRP-6 brings intense hunger and water retention; hexarelin desensitizes and affects cortisol and prolactin.

Does GHK-Cu develop tolerance or downregulation with long-term use?

GHK-Cu is a copper peptide studied mainly for skin and wound-healing applications, not growth hormone release, so it sits outside this GH ranking. On the tolerance question: there is limited controlled human data on long-term continuous GHK-Cu use, and claims of receptor desensitization or downregulation are not well established in the published literature. Most reported use is topical or short-course. Because the evidence base is thin, any tolerance pattern is uncertain, and long-term dosing should involve a licensed provider rather than self-experimentation.

Cost comparison

Approximate monthly costs for compounded peptides, where legally available:

• Sermorelin: $150 to $400, the most affordable.
• Ipamorelin: $200 to $400.
• CJC-1295: $250 to $450.
• Ipamorelin + CJC-1295 stack: $300 to $600.
• Tesamorelin: $300 to $1,200 compounded; brand Egrifta runs much higher, often $3,000 to $5,000+.
• GHRP-2 / GHRP-6: $150 to $350.

Safety, legality, and the FDA review

This is where access matters more than potency. In September 2023 the FDA placed several peptides, including ipamorelin and CJC-1295, into Category 2 of its 503A bulk-substances review, substances the agency flagged as raising significant safety concerns. That designation limited the ability of 503A compounding pharmacies to legally compound these peptides from bulk. In September 2024 the FDA removed ipamorelin acetate and CJC-1295 from Category 2 and referred them to the Pharmacy Compounding Advisory Committee, which began reviewing them in late 2024. Removal from Category 2 did not automatically clear them for compounding; the advisory review and a notice-and-comment period still have to play out. Sermorelin and tesamorelin are treated differently because they have or had FDA-approved forms. Many of the other peptides are sold as research chemicals with no quality oversight. Work with a licensed provider and a reputable pharmacy, and treat any "research only" source as unverified.

Frequently asked questions

What is the best growth hormone peptide? No single one is best for everyone. Ipamorelin + CJC-1295 is the most popular for balanced release; tesamorelin has the strongest evidence; sermorelin is the gentlest.

What is the best GHRP? Ipamorelin, because it selectively stimulates release with minimal cortisol, prolactin, or hunger effects. GHRP-2 and GHRP-6 are more potent but have more side effects.

Ipamorelin vs GHRP-2: which is better? Ipamorelin is cleaner with fewer side effects. GHRP-2 gives stronger release but raises cortisol and prolactin. Most prefer ipamorelin for long-term use.

GHRP-6 vs sermorelin: what is the difference? GHRP-6 is a ghrelin mimetic causing strong release and intense hunger; sermorelin is a gentler GHRH analog. Different receptors, sometimes combined.

What is the best HGH on the market? True HGH (somatropin) is synthetic growth hormone available by prescription for diagnosed deficiency. For people exploring natural support, secretagogue stacks like ipamorelin + CJC-1295 are popular, but they are not the same as prescription HGH.

Are growth hormone peptides legal? Status varies and is in flux. Sermorelin and tesamorelin have FDA-approved uses. Ipamorelin and CJC-1295 were placed in a restricted compounding category in September 2023, then removed in September 2024 and sent to an FDA advisory committee for review, so their compounding status is still being decided. Work with a licensed provider.

Does GHK-Cu lose effectiveness with long-term use? The evidence is limited. GHK-Cu is studied mainly for skin and healing, not GH release, and controlled long-term data is thin, so tolerance or downregulation claims are not well established.

Which peptide is most affordable? Sermorelin, at roughly $150 to $400 per month compounded, is generally the least expensive growth hormone secretagogue.

# Sources

• FDA, bulk drug substances and 503A interim policy (Category 2 listing September 2023; removal of ipamorelin and CJC-1295 September 2024): https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca
• FDA, Pharmacy Compounding Advisory Committee materials (ipamorelin, CJC-1295 review, 2024): https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
• FDA, Egrifta (tesamorelin) approval for HIV-associated lipodystrophy: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
• FDA, Macrilen (macimorelin) approval for GH-deficiency diagnosis: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205598
• Pickart L, Margolina A, GHK-Cu peptide review (Int J Mol Sci, 2018): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/
• Sigalos JT, Pastuszak AW, review of growth hormone secretagogues (Sex Med Rev, 2018): https://pubmed.ncbi.nlm.nih.gov/28526632/